ALK and non-small cell lung carcinoma: In the MYSTIC study, 1118 NSCLC cases with previously untreated EGFR and ALK wild-type NSCLC were categorized into treatment: chemotherapy alone, durvalumab, durvalumab plus four doses of tremelimumab, or durvalumab plus tremelimumab [123].